Photo from wikipedia
The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. Researchers… Click to show full abstract
The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. Researchers also found that side effects associated with other drugs in this class were no more common in the placebo group than the darolutamide group.
Keywords:
slows metastasis;
darolutamide;
darolutamide slows;
cancer;
prostate cancer
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!